Lynora Saxinger Selected Research

Infections

2/2023	Fidaxomicin to prevent recurrent Clostridioides difficile: what will it cost in the USA and Canada?
4/2022	The impact of shifting demographics, variants of concern and vaccination on outcomes during the first 3 COVID-19 waves in Alberta and Ontario: a retrospective cohort study.
1/2021	Treatment of moderate to severe respiratory COVID-19: a cost-utility analysis.
10/2020	COVID-19 screening of asymptomatic patients admitted through emergency departments in Alberta: a prospective quality-improvement study.
12/2017	Bacterial infections in acute variceal hemorrhage despite antibiotics-a multicenter study of predictors and clinical impact.
3/2015	Prevalence of antimicrobial use in a network of Canadian hospitals in 2002 and 2009.
4/2013	Two suspected cases of immunoglobulin-mediated interference causing falsely low vancomycin concentrations with the Beckman PETINIA method.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lynora Saxinger Research Topics

Disease

7	Infections 02/2023 - 04/2013
4	COVID-19 01/2023 - 01/2021
1	Rheumatic Diseases (Rheumatism) 01/2023
1	Vasculitis (Vasculitides) 01/2023
1	HIV Infections (HIV Infection) 01/2022
1	Clostridium Infections 11/2021
1	Respiratory Tract Infections (Respiratory Tract Infection) 01/2021
1	Biliary Liver Cirrhosis (Primary Biliary Cirrhosis) 01/2019
1	Fibrosis (Cirrhosis) 12/2017
1	Hemorrhage 12/2017
1	Bacterial Infections (Bacterial Infection) 12/2017
1	Cross Infection (Nosocomial Infection) 03/2015
1	Felty Syndrome (Syndrome, Felty's) 04/2013
1	Pneumonia (Pneumonitis) 04/2013

Drug/Important Bio-Agent (IBA)

2	COVID-19 VaccinesIBA 01/2023 - 01/2023
2	VaccinesIBA 01/2023 - 01/2023
1	FidaxomicinIBA 02/2023
1	AntigensIBA 01/2023
1	casirivimab and imdevimab drug combinationIBA 01/2022
1	Anti-Retroviral Agents (Antiretroviral Agents)IBA 01/2022
1	remdesivirIBA 01/2021
1	Oxygen (Dioxygen)IBA 01/2021
1	Dexamethasone (Maxidex)FDA LinkGeneric 01/2021
1	Lopinavir FDA Link 01/2019
1	Emtricitabine (Emtriva)FDA Link 01/2019
1	Tenofovir (Viread)FDA Link 01/2019
1	Alkaline PhosphataseIBA 01/2019
1	Reverse Transcriptase InhibitorsIBA 01/2019
1	Ritonavir (Norvir)FDA Link 01/2019
1	Anti-Bacterial Agents (Antibiotics)IBA 12/2017
1	Anti-Infective Agents (Microbicides)IBA 03/2015
1	CoagulaseIBA 04/2013
1	Vancomycin FDA LinkGeneric 04/2013

Therapy/Procedure

1	Length of Stay 04/2022
1	Fecal Microbiota Transplantation 11/2021
1	Critical Care (Surgical Intensive Care) 01/2021
1	Personal Protective Equipment 10/2020
1	Highly Active Antiretroviral Therapy (HAART) 01/2019
1	Antibiotic Prophylaxis 12/2017
1	Therapeutics 12/2017